Brief: Vistagen Announces Completion Of Last Patient, Last Visit In Phase 1 Clinical Trial Of Itruvone
08/03/2023 17:45
March 8 (Reuters) - Vistagen Therapeutics Inc VTGN.O :
* VISTAGEN ANNOUNCES COMPLETION OF LAST PATIENT, LAST VISIT
IN
PHASE 1 CLINICAL TRIAL OF ITRUVONE (PH10), AN INVESTIGATIONAL
PHERINE NASAL SPRAY FOR MAJOR DEPRESSIVE DISORDER
* VISTAGEN THERAPEUTICS INC - TOP LINE RESULTS ANTICIPATED
IN Q2
2023
Source text for Eikon: ID:nBwbWnfDSa
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors